Literature DB >> 6179574

Peptidase inhibitors reduce opiate narcotic withdrawal signs, including seizure activity, in the rat.

C Pinsky, A K Dua, F S LaBella.   

Abstract

Narcotic withdrawal was precipitated by administration of naloxone in a low dose at 2 h after the final dose of morphine in a 9-day dependency-inducing schedule. Withdrawal was characterized by leaps, increased nocifensor activity and by cerebral cortical epileptiform activity, the latter not generally reported to be prominent in narcotic withdrawal. Single large doses of morphine did not provoke epileptiform activity at 2 h postinjection but did induce an acute opioid dependency wherein a moderately high dose of naloxone, ineffective in non-dependent rats, provoked upward leaping and electrocortical epileptiform activity. Pretreatment of the 9-day dependent rats with peptidase inhibitors, administered intracerebroventricularly, significantly reduced withdrawal severity including the epileptiform activity. We propose that peptidase inhibitors protect certain species of endogenous opioids and/or other neuropeptides that tend to suppress expression of the narcotic withdrawal syndrome. Furthermore, our findings suggest that epileptiform activity is a nascent form of cerebral activity hitherto largely unnoticed in narcotic withdrawal and that neuropeptides may be involved in certain epileptic states.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179574     DOI: 10.1016/0006-8993(82)90253-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  Proteases of human brain.

Authors:  A Pope; R A Nixon
Journal:  Neurochem Res       Date:  1984-03       Impact factor: 3.996

2.  Is this 'complicated' opioid withdrawal?

Authors:  S R Parkar; R Seethalakshmi; S Adarkar; S Kharawala
Journal:  Indian J Psychiatry       Date:  2006-04       Impact factor: 1.759

3.  Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.

Authors:  S J Livingston; R D Sewell; K F Rooney; H J Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.